Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A research consortium, in which the Oxford Consortium for Islet Transplantation is a member, has been awarded major new EU funding to develop novel treatment options for reversing diabetes.

The DRIVE (Diabetes Reversing Implants with enhanced Viability and long-term Efficacy) consortium involves fourteen partners from seven European countries and has received €8.9 million funding as part of the Horizon 2020 Research and Innovation Framework Programme.

The DRIVE programme will develop natural materials and new surgical devices to enhance the transplant and survival of insulin producing pancreatic islets for the treatment of diabetes.

Read more

Similar stories

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.

Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells

Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.

Daily contact COVID-19 testing for students effective at controlling transmission in schools

A study by the University of Oxford has found that daily testing of secondary school students who were in contact with someone with COVID-19 was just as effective in controlling school transmission as the current 10-day contact isolation policy.